{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:14:55Z","timestamp":1760897695205},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1038\/ncponc0346","type":"journal-article","created":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T15:09:15Z","timestamp":1134400155000},"page":"S30-S35","source":"Crossref","is-referenced-by-count":63,"title":["Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies"],"prefix":"10.1038","volume":"2","author":[{"given":"Steven D","family":"Gore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl 6","key":"BFncponc0346_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/10732748040110S601","volume":"11","author":"A List","year":"2004","unstructured":"List A (2004) New paradigm in the management of myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 2","journal-title":"Cancer Control"},{"key":"BFncponc0346_CR2","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD et al. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671\u20133674","journal-title":"Blood"},{"key":"BFncponc0346_CR3","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429\u20132440","journal-title":"J Clin Oncol"},{"key":"BFncponc0346_CR4","doi-asserted-by":"crossref","unstructured":"List AF et al. (2004) Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program): 297\u2013317","DOI":"10.1182\/asheducation-2004.1.297"},{"key":"BFncponc0346_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.5-6-454","volume":"5","author":"O Bruserud","year":"2000","unstructured":"Bruserud O et al. (2000) Induction of differentiation and apoptosis\u2014a possible strategy in the treatment of adult AML. Oncologist 5: 454\u2013462","journal-title":"Oncologist"},{"key":"BFncponc0346_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cncr.11935","volume":"100","author":"F Ravandi","year":"2004","unstructured":"Ravandi F et al. (2004) New agents in acute myeloid leukemia and other myeloid disorders. Cancer 100: 441\u2013454","journal-title":"Cancer"},{"key":"BFncponc0346_CR7","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1200\/jco.2005.23.16_suppl.6543","volume":"23","author":"HI Saba","year":"2005","unstructured":"Saba HI et al. (2005) Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs. supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS) [abstract]. J Clin Oncol 23: 6543","journal-title":"J Clin Oncol"},{"key":"BFncponc0346_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"P Wijermans","year":"2000","unstructured":"Wijermans P et al. (2000) Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18: 956\u2013962","journal-title":"J Clin Oncol"},{"key":"BFncponc0346_CR9","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042\u20132054","journal-title":"N Engl J Med"},{"key":"BFncponc0346_CR10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.V104.11.469.469","volume":"104","author":"SD Gore","year":"2004","unstructured":"Gore SD et al. (2004) Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate [abstract]. Blood 104: 469","journal-title":"Blood"},{"key":"BFncponc0346_CR11","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1200\/jco.2005.23.16_suppl.6544","volume":"23","author":"G Garcia-Manero","year":"2004","unstructured":"Garcia-Manero G et al. (2004) Results of a phase I\/II study of the combination of 5-aza-2' deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia [abstract]. J Clin Oncol 23: 6544","journal-title":"J Clin Oncol"},{"key":"BFncponc0346_CR12","first-page":"A1408","volume":"102","author":"I Gojo","year":"2003","unstructured":"Gojo I et al. 2003 Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or relapsed hematologic malignancies [abstract]. Blood 102: A1408","journal-title":"Blood"},{"key":"BFncponc0346_CR13","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1200\/jco.2004.22.14_suppl.3027","volume":"22","author":"G Garcia-Manero","year":"2004","unstructured":"Garcia-Manero G et al. (2004) Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS) [abstract]. J Clin Oncol 22: 3027","journal-title":"J Clin Oncol"},{"key":"BFncponc0346_CR14","first-page":"171b","volume":"94","author":"A Raza","year":"1999","unstructured":"Raza A et al. (1999) Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (Enbrel) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood 94: 171b","journal-title":"Blood"},{"key":"BFncponc0346_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1515\/bchm.1998.379.8-9.1113","volume":"379","author":"C Deng","year":"1998","unstructured":"Deng C et al. (1998) Role of the ras-MAPK signaling pathway in the DNA methyltransferaes response to DNA hypomethylation. Biol Chem 379: 1113\u20131120","journal-title":"Biol Chem"},{"key":"BFncponc0346_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1200\/JCO.2004.08.082","volume":"22","author":"R Kurzrock","year":"2004","unstructured":"Kurzrock R et al. (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22: 1287\u20131292","journal-title":"J Clin Oncol"},{"key":"BFncponc0346_CR17","first-page":"186","volume":"4","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ (2005) Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 4: 186\u2013190","journal-title":"Curr Hematol Rep"},{"key":"BFncponc0346_CR18","first-page":"5902","volume":"62","author":"M Esteller","year":"2002","unstructured":"Esteller M et al. (2002) Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 62: 5902\u20135905","journal-title":"Cancer Res"},{"key":"BFncponc0346_CR19","first-page":"2","volume":"61","author":"FF Ferrara","year":"2001","unstructured":"Ferrara FF et al. (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61: 2\u20137","journal-title":"Cancer Res"},{"key":"BFncponc0346_CR20","first-page":"A1545","volume":"102","author":"J Gotlib","year":"2003","unstructured":"Gotlib J et al. (2003) Phase II study of bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results [abstract]. Blood 102: A1545","journal-title":"Blood"},{"key":"BFncponc0346_CR21","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","volume":"10","author":"JE Karp","year":"2004","unstructured":"Karp JE et al. (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10: 3577\u20133585","journal-title":"Clin Cancer Res"},{"key":"BFncponc0346_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A et al. (2005) Efficacy of lenalidomide in MDS. N Engl J Med 352: 349\u2013357","journal-title":"N Engl J Med"},{"key":"BFncponc0346_CR23","doi-asserted-by":"publisher","first-page":"A1815","DOI":"10.1182\/blood-2004-07-2627","volume":"104","author":"D Douer","year":"2004","unstructured":"Douer D et al. (2004) Treatment of acute myelogenous leukemia (Non-APL) with intravenous Trisenox\u00ae (arsenic trioxide) and ascorbic acid: preliminary results [abstract]. Blood 104: A1815","journal-title":"Blood"},{"key":"BFncponc0346_CR24","first-page":"3658","volume":"8","author":"NJ Bahlis","year":"2002","unstructured":"Bahlis NJ et al. (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma. Clin Cancer Res 8: 3658\u20133668","journal-title":"Clin Cancer Res"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0346","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:40:31Z","timestamp":1684442431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":24,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["BFncponc0346"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0346","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}